During the past decade, HNO-ZENTRUM am Kudamm conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "HNO-ZENTRUM am Kudamm" #1 collaborator was "Aerin Medical" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "HNO-ZENTRUM am Kudamm" are "Chronic Rhinitis" (1 trials), "Meniere Disease" (1 trials) and "Nasal Obstruction, Bilateral" (1 trials). Many other conditions were trialed in "HNO-ZENTRUM am Kudamm" in a lesser frequency.

Most popular intervention types in "HNO-ZENTRUM am Kudamm" are "Device" (2 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "OTO-104" (1 trials), "Placebo" (1 trials), "RhinAer ARC Stylus" (1 trials) and "Vivaer® ARC Stylus" (1 trials). Other intervention names were less common.

The vast majority of trials in "HNO-ZENTRUM am Kudamm" are 3 trials for "All" genders.

Currently, there are NaN active trials in "HNO-ZENTRUM am Kudamm". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in HNO-ZENTRUM am Kudamm, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in HNO-ZENTRUM am Kudamm, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".